In addition, we also predicted the response to immunotherapy in subgroups of gliomas with high and low expression of SLC11A1, and the results showed that the subgroup with high expression of SLC11A1 had a higher proportion of response to immunotherapy compared to the low expression group(Figure 6G). This evidence concerns the gene SLC11A1 and central nervous system cancer.